Literature DB >> 21216282

Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease.

Ingrid C Gaemers1, Jan M Stallen, Cindy Kunne, Christian Wallner, Jochem van Werven, Aart Nederveen, Wouter H Lamers.   

Abstract

UNLABELLED: The major risk factors for non-alcoholic fatty liver disease (NAFLD) are obesity, insulin resistance and dyslipidemia. The cause for progression from the steatosis stage to the inflammatory condition (non-alcoholic steatohepatitis (NASH)) remains elusive at present. Aim of this study was to test whether the different stages of NAFLD as well as the associated metabolic abnormalities can be recreated in time in an overfed mouse model and study the mechanisms underlying the transition from steatosis to NASH. Male C57Bl/6J mice were subjected to continuous intragastric overfeeding with a high-fat liquid diet (HFLD) for different time periods. Mice fed a solid high-fat diet (HFD) ad libitum served as controls. Liver histology and metabolic characteristics of liver, white adipose tisue (WAT) and plasma were studied. Both HFD-fed and HFLD-overfed mice initially developed liver steatosis, but only the latter progressed in time to NASH. NASH coincided with obesity, hyperinsulinemia, loss of liver glycogen and hepatic endoplasmatic reticulum stress. Peroxisome proliferator-activated receptor γ (Pparγ), fibroblast growth factor 21 (Fgf21), fatty acid binding protein (Fabp) and fatty acid translocase (CD36) were induced exclusively in the livers of the HFLD-overfed mice. Inflammation, reduced adiponectin expression and altered expression of genes that influence adipogenic capacity were only observed in WAT of HFLD-overfed mice. IN
CONCLUSION: this dietary mouse model displays the different stages and the metabolic settings often found in human NAFLD. Lipotoxicity due to compromised adipose tissue function is likely associated with the progression to NASH, but whether this is cause or consequence remains to be established.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21216282     DOI: 10.1016/j.bbadis.2011.01.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  23 in total

1.  Dietary supplementation with methyl donors reduces fatty liver and modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet.

Authors:  P Cordero; A M Gomez-Uriz; J Campion; F I Milagro; J A Martinez
Journal:  Genes Nutr       Date:  2012-05-31       Impact factor: 5.523

2.  Ethnic differences in the link between insulin resistance and elevated ALT.

Authors:  Mark D Deboer; R Constance Wiener; Barrett H Barnes; Matthew J Gurka
Journal:  Pediatrics       Date:  2013-08-12       Impact factor: 7.124

3.  Ω3-Polyunsaturated fatty acids prevent lipoperoxidation, modulate antioxidant enzymes, and reduce lipid content but do not alter glycogen metabolism in the livers of diabetic rats fed on a high fat thermolyzed diet.

Authors:  Adriano M de Assis; Anderson Rech; Aline Longoni; Liane N Rotta; Cristiane C Denardin; Matheus A Pasquali; Diogo O Souza; Marcos L S Perry; José C Moreira
Journal:  Mol Cell Biochem       Date:  2011-10-12       Impact factor: 3.396

4.  DNA microarray analysis of genes differentially expressed in adipocyte differentiation.

Authors:  Chunyan Yin; Yanfeng Xiao; Wei Zhang; Erdi Xu; Weihua Liu; Xiaoqing Yi; Ming Chang
Journal:  J Biosci       Date:  2014-06       Impact factor: 1.826

5.  Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.

Authors:  Brett M McGettigan; Rachel H McMahan; Yuhuan Luo; Xiaoxin X Wang; David J Orlicky; Cara Porsche; Moshe Levi; Hugo R Rosen
Journal:  J Biol Chem       Date:  2016-09-07       Impact factor: 5.157

6.  Hepatic Steatosis Accompanies Pulmonary Alveolar Proteinosis.

Authors:  Alan N Hunt; Anagha Malur; Tual Monfort; Pavlos Lagoudakis; Sumeet Mahajan; Anthony D Postle; Mary Jane Thomassen
Journal:  Am J Respir Cell Mol Biol       Date:  2017-10       Impact factor: 6.914

7.  Zonation of hepatic fat accumulation: insights from mathematical modelling of nutrient gradients and fatty acid uptake.

Authors:  Jana Schleicher; Uta Dahmen; Reinhard Guthke; Stefan Schuster
Journal:  J R Soc Interface       Date:  2017-08       Impact factor: 4.118

8.  Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis.

Authors:  Priya Handa; Bryan D Maliken; James E Nelson; Vicki Morgan-Stevenson; Donald J Messner; Barjinderjit K Dhillon; Heather M Klintworth; Mary Beauchamp; Matthew M Yeh; Clinton T Elfers; Christian L Roth; Kris V Kowdley
Journal:  Hepatology       Date:  2014-05-27       Impact factor: 17.425

9.  Scp-2/Scp-x ablation in Fabp1 null mice differentially impacts hepatic endocannabinoid level depending on dietary fat.

Authors:  Gregory G Martin; Drew R Seeger; Avery L McIntosh; Sarah Chung; Sherrelle Milligan; Danilo Landrock; Lawrence J Dangott; Mikhail Y Golovko; Eric J Murphy; Ann B Kier; Friedhelm Schroeder
Journal:  Arch Biochem Biophys       Date:  2018-05-12       Impact factor: 4.013

10.  Loss of fatty acid binding protein-1 alters the hepatic endocannabinoid system response to a high-fat diet.

Authors:  Gregory G Martin; Danilo Landrock; Sarah Chung; Lawrence J Dangott; Avery L McIntosh; John T Mackie; Ann B Kier; Friedhelm Schroeder
Journal:  J Lipid Res       Date:  2017-10-02       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.